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Radiation quality indices (QI), tumor control probability (TCP), and normal tissue complication 
probability(NTCP) were evaluated for ideal single and double plane HDR interstitial implants. In the analysis, 
geometrically–optimized at volume (GOV) treatment plans were generated for different values of 
inter–source–spacing (ISS) within the catheter, inter–catheter–spacing (ICS), and inter–plane–spacing (IPS) for 
single -  and double - plane implants. The dose volume histograms (DVH) were generated for each plan, and 
the coverage volumes of 100%, 150%, and 200% were obtained to calculate QIs, TCP, and NTCP. Formulae for 
biologically effective equivalent uniform dose (BEEUD), for tumor and normal tissues, were derived to calculate 
TCP and NTCP. Optimal values of QIs, except external volume index (EI), and TCP were obtained at ISS = 1.0 
cm, and ICS = 1.0 cm, for single–plane implants, and ISS = 1.0 cm, ICS = 1.0 cm, and IPS = 0.75 to 1.25 cm, for 
double – plane implants. From this study, it is assessed that ISS = 1.0 cm, ICS = 1.0 cm, for single - plane implant 
and IPS between 0.75 cm to 1.25 cm provide better dose conformity and uniformity.   
Key words: HDR interstitial implants, quality indices, inter-source-spacing, inter-catheter-spacing, geometrical – optimization 
at volume, biologically effective equivalent uniform dose. 
INTRODUCTION 
Use of computerized, remote controlled, 
high-dose-rate (HDR) brachytherapy units, and 
treatment planning systems provide conformal dose 
coverage to the target volume and minimum possible 
dose to surrounding normal tissues / critical organs.  
However, the basic principles of dosimetry systems [1 
– 4] still influence the criteria of the source placement 
(activity distribution) and dose distributions in 
brachytherapy applications. In the HDR 
brachytherapy applications, such as in the treatment 
of carcinoma of the cervix (Ca.Cx.), the basic rules of 
the Manchester system [1] are still followed in many 
clinics World wide. In the HDR interstitial 
brachytherapy (ISBT) implants  none of the classical 
dosimetry system [1 – 4] is followed. This is because 
modern HDR units have a high activity miniature 
type single stepping source, which offers an 
advantage of varying source positions (dwell 
positions) and time (dwell time) to a particular dwell 
position to obtain an appropriate dose distribution 
and isodose geometry. For HDR implants, a new 
dosimetry system, known as stepping source 
dosimetry system (SSDS) [5], has been devised in 
which source and dose distribution rules were formed 
using the selected basic rules of the Paris and the 
Manchester dosimetry systems with some 
modifications.  
Kwan et al [6] have done a computerized 
dosimetric study to determine optimal source and 
ribbon separation for single – plane implants, and the 
ribbon and plane separation of for double plane 
implants were studied with respect to the dose 
homogeneity, for single – and double – plane iridium 
– 192 (Ir – 192) implants. In another study of Quimby 
type breast implants, interplanar spacing, based on the 
implant sizes, was studied [7].    None of the study has 
so far able to optimize these parameter for HDR single 
– and double – plane implants. In this work, we 
performed a computerized dosimetric study of HDR 
implants to find out optimal values of inter – source – 
spacing (ISS), within the catheter, and inter – catheter 
– spacing (ICS), within the target volume (TV), for 
ideal single plane implants. This was done by 
computing various radiation quality indices (QI) for 
geometrically optimized at volume (GOV) treatment 
plans. The GOV mode of optimization was chosen due 
to its simplicity, otherwise reader can choose any Int. J. Med. Sci. 2008, 5 
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other suitable mode of optimization in practice. The  
inter – plane – spacing (IPS) for ideal double plane 
implants has also been determined using optimal 
values of ISS and ICS, obtained from single plane 
implants, by computing above said QIs for GOV 
treatment plans. The concept of Biologically Effective 
Equivalent Uniform Dose (BEEUD) has been 
introduced to calculate the tumor control probability 
(TCP) [8, 9] and normal tissue complications 
probability (NTCP) [10] for these HDR plans. 
METHODS AND MATERIALS 
Dosimetric parameters 
To investigate ideal values of ISS, ICS and IPS in 
HDR interstitial implants, for which nearly ideal dose 
distribution within the target volume and maximum 
sparing of the surrounding normal tissues / organs, 
can be achieved, a quantitative analysis of ideal single 
and double plane implants has been done for different 
ISS and ICS values. The analysis is performed by 
computing and comparing different QIs, TCP, and 
NTCP for GOV treatment plans of these implants. The 
quality indices used in this study are: the coverage 
index (CI), the external volume index (EI), the relative 
dose homogeneity index (DHI), the overdose index 
(ODI), and the dose non-uniformity ratio (DNR), and 
are defined as: 
1. Coverage Index (CI): The fraction of the target 
volume that receives a dose equal to or greater than 
the reference dose [11]. 
CI = TVDref / T V             … . ( 1 )   
2.  External Volume Index (EI): The ratio of the 
volume of normal tissue that receives a dose equal to 
or greater than the reference dose to the volume of the 
target [11]. 
EI = NTVDref / T V              …. (2) 
3. Relative Dose Homogeneity Index (DHI): This 
is defined as the ratio of the target volume which 
receives a dose in the range of 1.0 to 1.5 times of the 
reference dose to the volume of the target that receives 
a dose equal to or greater than the reference dose [11]. 
DHI = [TVDref  –   T V 1.5Dref]/TVDref             …. (3) 
4. Overdose Volume Index (ODI): This is the ratio 
of the target volume which receives a dose equal to or 
more than 2.0 times of the reference dose to the 
volume of the target that receives a dose equal to or 
greater than the reference dose [11]. 
ODI = TV2.0Dref /TVDref                …. (4) 
5. Dose Non-uniformity Ratio (DNR): This is the 
ratio of the target volume which receives a dose equal 
to or greater than 1.5 times of the reference dose to the 
volume of the target which receives a dose equal to or 
greater than the reference dose [12]. 
DNR = TV1.5Dref /TVDref    … .   ( 5 )  
Conditions for an ideal implant are where the 
values of QIs should be as follows 
CI = 1, EI = 0, DHI = 1, ODI = 0, and DNR = 0 
To compute above defined QIs, for single plane 
implants, ideal targets of target volumes of the 
dimensions of Length (L= 6.0 cm) × Width (W= 5.0 cm 
) × Thickness (T = 1.0 cm) have been taken into 
account. While changing the values of ISS and / or 
ICS, sometimes extra length and width of target 
v o l u m e  w e r e  a l s o  a d d e d  t o  k e e p  c o n s t a n t  d i s t a n c e  
between target surface and peripheral dwell positions 
and / or target surface and peripheral catheters. The 
catheters and peripheral dwell positions were placed 
within 0.5 cm of the boundary of the target volume. 
Treatment plans were generated using PLATO 
(Nucletron BV, Veenendaal, The Netherlands) 3 – D 
treatment planning system. The dose points were 
placed on the surface of the target volume relative to 
the active dwell positions.    All the dose points, in the 
implant, were used for dose normalization for the 
total dose of 42 Gy with 3.5 Gy per fraction.  The 
Cumulative DVH (cDVH) for GOV treatment plans 
were generated for different values of ISS and ICS. 
The values of ICS vary from 0.5 cm to 2.0 cm, in steps 
of 0.25 cm. For each ICS values, the ISS varies from 
0.25 cm to 2.0 cm in steps of 0.25 cm. In each treatment 
plan, the isodose surfaces of 100% (42 Gy), 150% (63 
Gy) and 200% (84 Gy) were generated to find out the 
respective dose coverage volumes. By comparing the 
QIs for all treatment plans, the optimal values of ISS 
and ICS were obtained for which QIs to be the closest 
values of that of an ideal implant. 
The GOV treatment plans were also generated 
for double plane implants using optimal values of ISS 
and ICS, obtained from single plane implants QI 
analysis. The cDVHs were generated for inter – plane 
–spacing (IPS) vary from 0.5 cm to 2.0 cm in steps of 
0.25 cm and the coverage volumes for the isodose 
surfaces of 100%, 150% and 200% were obtained from 
the cDVHs, as calculated for single plan implants, to 
compute the above said QIs for each treatment plan 
with different IPS value. 
Radiobiological models 
The linear quadratic (LQ) model provides a 
simple way to describe dose – response of different 
fractionation schemes, in terms of the Biologically 
Effective Dose (BED) [13]. The BED for HDR ISBT [9] 
for a total dose of D (Gy) delivered with dose d (Gy) 
per fraction can be written by   
BED = D[1 + G d/(α/ ß ) ]            … .   ( 6 )  Int. J. Med. Sci. 2008, 5 
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Where α/ß ratio is the tissue specific parameter 
and is the ratio of the coefficients of lethal damage to 
the sublethal damage, and G is the factor accounting 
for incomplete repair of sublethal damage during 
interfraction interval between the fractions. In this 
study, it is assumed that the time interval between the 
fractions is sufficient enough to allow the full repair of 
the sublethal damage, hence G is taken as 1. 
The tumor control probability (TCP) [8, 9] for 
uniform dose distribution within the target volume is 
given by   
TCP = exp[ - ρ V exp(-α BEDt)]          ….  (7) 
Where ρ, V, α, and BEDt are the clonogenic cell 
density, target volume, coefficient of lethal damage 
(radio – sensitivity of lethal damage), and BED for the 
target, respectively. The dose distribution of HDR 
ISBT within target volume is highly non – uniform 
and has high dose gradient, hence equation (7) can not 
be directly applied to compute accurate TCP. Hence, 
to get an appropriate expression of TCP for HDR ISBT 
implant different regions of HDR ISBT implant have 
been considered (Figure 1). It is also shown that target 
volume is divided into four regions which are (1) the 
region which receives a dose less than the reference 
dose, (2) the region which receives a dose in the range 
of 1.0 to 1.5 times of the reference dose, (3) the region 
which receives a dose in the range of 1.5 to 2.0 times of 
the reference dose, and (4) the region which receives a 
dose equal to or more than 2.0 times of the reference 
dose. Each region of target volume has its own 
BEEUD. The expression of BEEUD, for tumor, is 
derived in Apendix – A, where it is considered that 
there is a non – uniform dose distribution within the 
target volume. The target volume is divided into ‘n’ 
number of voxels of small enough volume. So it can be 
assumed that the dose distribution within the voxel is 
uniform. The expression for BEEUD, given in equation 
(e) of Appendix – A, is written as 
BEEUDt = -(1/α) ln[(1/V) Σivi exp{ - α BEDti}]   …. 
(8) 
Where V is the target volume, vi is the volume of 
ith voxel of the target volume, and BEDti is the BED of 
the ith voxel of the target volume. The subscript ‘t’ 
denotes the target volume. With the use of BEEUD of 
each region, shown in Figure 1, the TCP may be 
written as 
TCP = TCP1 × TCP2 × TCP3 × TCP4       … .   ( 9 )  
Where the terms TCP1, TCP2, TCP3, and TCP4 are 
the TCPs of above defined regions of the target 
volume, respectively. The expressions of these terms 
are given as follows 
1. The TCP for the region of target volume which 
receives a dose less than the reference dose 
TCP1 = exp[ - ρ (TV – TVDref) exp( - α BEEUDt1)] 
By rearranging and using the value of equation 
(1), we may write 
TCP1 = exp[ - ρ TVDref{(1 – CI)/CI} exp( - α BEEUDt1)]   
…. (9a) 
2. The TCP for the region of target volume that 
receives a dose in the range of 1.0 to 1.5 times of the 
reference dose 
 TCP2 = exp[ - ρ (TVDref – TV1.5Dref) exp( - α BEEUDt2)] 
Using the value of equation (3), we may write 
 TCP2 = exp[ - ρ TVDref . DHI exp( - α BEEUDt2) ]       
…. (9b) 
3. The TCP for the region of target volume that 
receives a dose in the range of 1.5 to 2.0 times of the 
reference dose 
 TCP3 = exp[ - ρ (TV1.5Dref – TV2Dref) exp( - α BEEUDt3)] 
By rearranging and using the values of equations 
(4) & (5), we may write 
TCP3 = exp[ - ρ TVDref (DNR– ODI) exp( - α BEEUDt3)] 
…. (9c) 
4. The TCP for the region of target volume that 
receives a dose equal to or greater than 2 times of the 
reference dose 
TCP4 = exp[ - ρ TV2Dref  exp(  -  α BEEUDt4)]  
By using the value of equation (4), we may have 
the form of TCP4 
TCP4 = exp[ - ρ TVDref .ODI exp( - α BEEUDt4)]          
…. (9d) 
Now multiplying and rearranging equations 9(a) 
– 9(d), the expression of net TCP may be given by 
TCP = exp[–ρ TVDref {({1–CI}/CI) exp(–α 
BEEUDt1)+DHI exp(–α BEEUDt2) +(DNR– ODI) 
exp(–α BEEUDt3)+ODI exp(–α BEEUDt4)}]   ….  (10) 
Probably three radiobiological parameters, 
considered in the TCP formulation, such as clonogenic 
cell density (ρ), radio-sensitivity (α), and cell 
proliferation rate (Tp) influence the TCP 
phenomenological and are voxel dependent. In this 
work, it is assumed that first two parameters are 
constant throughout the target volume and influence 
of the cell proliferation rate is negligible.   
The radiobiologically based expression of normal 
tissue complication probability (NTCP) for uniform 
dose distribution within normal tissue / organ, was 
initially proposed by Kallman, et al [14] and was 
modified by Zaider and Amols [15]. Kehwar and 
Sharma [16] and Kehwar [10] have further extended 
this model for the multiple component (MC) and the 
linear quadratic (LQ) models, respectively. These 
extended forms, of the NTCP model for MC and LQ Int. J. Med. Sci. 2008, 5 
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models, were fitted to the normal tissue tolerance 
doses reported by Emami et al [17] at TD5/5 and TD50/5 
for partial volumes of different normal tissues / 
o r g a n s .  K e h w a r ’ s  [ 1 0 ]  N T C P  e q u a t i o n  o f  L Q  m o d e l  
may be written as 
NTCP = exp[– N0 v– k exp(– α BEDn)]   ….  (11) 
Where v and BEDn are the fractional partial 
volume (v=V/V0, here V and V0 are the partial volume 
and the reference volume of the normal tissue / organ, 
respectively) and BED of normal tissue / organ. The  
N0 and k are tissue-specific, non-negative adjustable 
parameters. The dose distribution outside the target 
volume within the adjacent normal tissue is highly 
non-uniform, hence equation (11) can not be applied 
to calculate NTCP for such a high dose gradient. For 
the purpose, entire volume of the normal tissue / 
organ is divided into two regions, viz (1) the region 
that receives a dose less than the reference dose, and 
(2) the region that receives a dose equal to or greater 
than the reference dose. Each region of normal tissue 
has its own BEEUD. The expression of BEEUD for 
normal tissue is derived in Apendix – B, where it is 
considered that there is a non-uniform dose 
distribution within the normal tissue, and is divided 
into ‘n’ number of very-very small sub-volumes 
(voxels). It has also been assumed that the dose 
distribution within a sub-volume is uniform. From 
equation (11), it is seen that the equation of NTCP is 
not an additive term of the volume, as TCP for TV, so 
the NTCP of voxels can not provide net NTCP of 
entire normal tissue. Therefore, equation (11) has been 
modified to account for addition of the volumes of the 
voxels, and the new term is known as the NTCP factor 
(NTCPF) which is written as 
  NTCPF = exp[(N0)-1/k Σi{(Vi/V0) exp[(α/k) BEDni]}]  
…. (12) 
Where V0 is the reference volume of the normal 
tissue / organ and Vi is the volume of ith voxel in the 
normal tissue / organ. The expression of BEEUD, 
from Appendix – B, for normal tissue is written by 
BEEUDn = (k/α) ln[Σi{(Vi/V0) exp[(α/k) BEDni]}]      
…. (13)   
With the use of BEEUD of each region of normal 
tissue / organ, the NTCPF may be written as 
NTCPF = NTCPFn1 × NTCPFn2  ….  (14)  
Where the terms NTCPFn1, and NTCPFn2 are the 
NTCPFs of above defined two normal tissue regions, 
respectively. The expressions of these terms are given 
as follows 
1. The NTCPF for the region of normal tissue / 
organ which receives a dose less than the reference 
dose 
NTCPFn1 = exp[(N0)–1/k(1/V0) (V – NTVDref) exp{(α/k) 
BEEUDn1}] 
Where, V, is the normal tissue volume of the 
normal tissue / organ. By rearranging and using the 
value of equation (2), we may write 
 NTCPFn1 = exp[(N0)–1/k(TV/V0) (V/TV – EI) exp{(α/k) 
BEEUDn1} ]      … .   ( 1 4 a )  
2. The NTCPF for the region of normal tissue / 
organ that receives a dose equal to or greater than the 
reference dose 
NTCPFn2 = exp[(N0)–1/k(1/V0) (NTVDref) 
exp{(α/k)BEEUDn2}] 
Using the value of equation (3), we may write 
NTCPFn2 = exp[(N0)–1/k(TV.EI/V0) 
exp{(α/k)BEEUDn2} ]      … .   ( 1 4 b )  
By adding and rearranging equations (14a) and 
(14b), the net NTCPF will be written as 
NTCPF = exp[(N0)–1/k(TV/V0)[(V/TV–EI) 
exp{(α/k)BEEUDn1}+(EI/V0) exp{(α/k)BEEUDn2}]]  
…. (15) 
The net NTCP from equation (15) is written by 
NTCP = (NTCPF)k   ….  (16) 
For statistical comparison, two tail unpaired 
t-student test is employed to the results of NO and 
GOV plans. 
RESULTS  
Dosimetric Analysis 
a) Single Plane Implant 
The curves were plotted for single plane implants 
between ISS and IQs, which are shown in Figures 2 to 
Figure 6. Figure 2 shows that the CI decreases from 
0.98 to 0.97 for the values of ISS, which may be 
considered almost constant. The slope of the linear 
lines is -0.006 for all ICS values. The CI at ISS = 1.0 cm 
and ICS = 1.0 cm are 0.98 these plans.   
Figure 3 shows that the value of EI increases in a 
linear trend insignificantly for all ICS values, and for 
any value of ISS. In these plans, the slopes of all linear 
lines remain almost constant with an average of 0.0012 
(0.0012, 0.0013).     
It is clear from Figure 4 that initially the value of 
DHI increases with increasing ISS and ICS and reaches 
to a maximum value at ISS = 1.0 cm and ICS = 1.0 cm, 
and then decreases with ISS. The values of DHI at ISS 
= 1.0 cm and ICS = 1.0 cm are 0.851 for these plans. 
The relation between ODI and ISS for different 
ICS values is given in Figure 5. It appears that the 
value of ODI decreases with increasing ISS and ICS 
and reaches to a minimum at ISS = 1.0 cm & ICS = 1.0 
cm, thereafter it starts increasing with ISS and ICS. Int. J. Med. Sci. 2008, 5 
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The values of ODI at ISS = 1.0 cm and ICS = 1.0 cm are 
0.079 for these plans. Figure 6 shows similar relation 
between DNR and ISS as between ODI and ISS.   
The calculated QIs for an ideal HDR implant 
reveals that at ISS = 1.0 cm and ICS = 1.0 cm, the 
values of DHI, ODI and DNR attain an optimal level. 
In this study, the values of QIs for single - plane 
implant at ISS =1.0 cm and ICS = 1.0 cm are CI = 0.98; 
EI = 0.062; DHI = 0.851; ODI = 0.079, and DNR = 0.149, 
respectively.  
 
Figure 1: Schematic diagram showing target volume (TV), 
portion of target volume (TVDref) that receives dose equal to or 
more than the reference dose  Dref, the isodose surface that 
receives 1.5 time of the reference dose (1.5 Dref), and that 
receives  2.0 times of the reference dose (2.0 Dref). 
 
Figure 2:  A quantitative comparison of CI calculated for 
varying ISS and ICS values for NO and GOV plans for ideal 
HDR single plane interstitial implants. 
 
Figure 3: Comparison of calculated EI for varying ISS and ICS 
for  GOV plans, of ideal HDR single plane interstitial implants. 
 
Figure 4: Comparison of calculated DHI for varying ISS and 
ICS for  GOV plans, of ideal HDR single plane interstitial 
implants. 
 
Figure 5: Comparison of calculated ODI for varying ISS and 
ICS for GOV plans, of ideal HDR single plane interstitial 
implants. 
 
Figure 6: Comparison of calculated DNR for varying ISS and 
ICS for  GOV plans, of ideal HDR single plane interstitial 
implants. 
 
b) Double Plane Implant 
For simplicity of the study, the best suitable 
values of ISS and ICS (ISS = 1.0 cm & ICS = 1.0 cm) for 
which DHI, ODI and DNR attain optimal values in 
single - plane implants, were used to construct the 
double plane implant. These values of ISS and ICS 
may not be optimal for double plane implants. The 
implant length and width were kept constant while 
the interplane separation (IPS) allowed to vary from 
0.5 cm to 2.0 cm in steps of 0.25 cm. The GOV plans 
were generated for each IPS and to find out the Int. J. Med. Sci. 2008, 5 
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volume coverage for 100%, 150% and 200% isodose 
surfaces the DVHs were generated. From above 
determined volumes, the QIs were computed and 
found that the variation of QIs with IPS is similar to 
that as of IQs with ISS. For IPS = 0.75 cm to 1.25 cm 
the QIs are optimal to treat a target of thickness from 
1.75 to 2.25 cm. The values of QIs for IPS = 1.0 cm are 
CI = 0.978, EI = 0.08, DHI = 0.88, ODI = 0.09 and DNR 
= 0.29. If the IPS is further increased beyond 1.25 cm 
the DHI decreases and ODI increases, and a cold spot 
is generated between the two planes. 
Plots between QIs and IPS, for both type of plans, 
were similar to that for single plan implants, hence to 
avoid repetition of the figures, we have not included 
in this paper.   
Radiobiological Analysis 
BEEUDs have been calculated using equation (8) 
for different portions of the TV with the use of α/β = 
10 Gy, α = 0.35 Gy-1 [13], and clonogenic cell density ρ 
= 107 [18] to calculate the net value of TCP using 
equation (10) for entire TV. In the calculation of 
BEEUD, for a particular region of the TV, the volume 
o f  t h a t  r e g i o n  i s  s u b d i v i d e d  i n t o  v e r y  s m a l l  
sub-volumes and it is assumed that there is a uniform 
dose distribution within each sub-volume. The plots 
between net TCPs and ISS are shown in Figure 7, 
where the TCP for ICS = 1.0 cm and ISS = 1.0 cm 
implant is higher compared to other ICS and ISS 
settings.  
 
Figure 7: Comparison of calculated TCP, based on LQ 
equation, for varying ISS and ICS for GOV plans, of ideal HDR 
single plane interstitial implants. 
 
To calculate the NTCP for normal tissue, the 
normal tissue / organ is divided into two regions, (i) 
the region that receives a dose less than the reference 
dose, and (ii) the region that receives a dose equal to 
or greater than the reference dose. For demonstration 
purpose and to simulate the lung complications in 
breast HDR implants, the BEEUDs values were 
calculated for each region of the normal tissue / organ 
using derived values of the parameters [10], N0 = 3.93, 
k =1.03, for combined set of lung tolerance data, and α 
= 0.075 Gy-1, for lung tolerance data of Emami et al 
[17] and published values of α/β = 6.9 Gy [19, 20].   
The plots of NTCP and ISS for different ICS setting are 
shown in Figure 8, where it is seen that the value of 
NTCP increases with increasing ICS and ISS and 
highest value was found at ICS = 2.0 cm and ISS = 2.0 
cm. Similar results were obtained for double plan 
implants, but to avoid repetition, the figures have not 
been included. 
 
 
Figure 8: Comparison of calculated NTCP, based on LQ 
equation, for varying ISS and ICS GOV plans, of ideal HDR 
single plane interstitial implants. 
 
DISCUSSION 
A number of quality indices have been proposed 
to evaluate LDR and HDR interstitial implants, such 
as, DHI and DNR proposed by Saw and 
Suntharalingam [21, 22] and Saw et al [12] for LDR 
interstitial brachytherapy and was adopted by 
Meertens et al [11] for the evaluation of HDR 
interstitial implants. Hence, in this study we used the 
QI values as defined by Meertens et al [11].   
The expressions for TCP and NTCP 
incorporating above defined QIs were derived in this 
work, and the effects of the variation in ISS and ICS 
were investigated in GOV plans of ideal HDR 
interstitial implants. Figures – 7 and 8 show the effect 
of variation in ISS and ICS on TCP and NTCP. The 
calculations of TCP and NTCP, done by most of the 
investigators [8, 9, 10, 14, 15, 16], based on either entire 
target or normal tissue volume with a single dose or 
by dividing the entire volume in small voxels. In this 
work, we have opted different approach, where TV 
and NTV are divided into 4 and 2 parts to define 
target and normal tissue related QIs, respectively. The 
expressions of BEEUD were derived for these parts of 
TV and NTV, and were incorporated into the 
expression of the TCP and NTCP.         
In the Paris dosimetry system, designed for Ir – 
192 wires and ribbons, suggests that to obtain a better Int. J. Med. Sci. 2008, 5 
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coverage of the TV, one have to increase the active 
length of the catheters, and peripheral catheters have 
to be placed outside the target volume. But by doing 
so, this also increases the EI which consequently will 
increase the NTCP. Many researchers investigated this 
aspect and stated that active length of the catheters 
can be reduced compared to non optimized plans with 
uniform dwell times [5, 23, 24, 25] by properly 
optimizing the implant, because in optimization the 
dwell times of the dwell positions at the ends of the 
catheters and peripheral catheters are increased to 
compensate for the lack of source locations beyond the 
outermost dwell positions.   
Kwan et al [6] have reported that with respect to 
the dose homogeneity, within the implants, the 
optimal source and ribbon separation for single – 
plane implants was found to be 1.0 cm, and the ribbon 
and plane separation of 1.5 cm was found for double 
plane implants, maintaining a 1.0 cm source 
separation. Zwicker et al [7] found that interplanar 
spacing in Quimby type breast implants was implant 
size dependent.   
Major et al [26] have studied the effect of source 
step size and catheter separation on DNR for 
non-optimized and optimized interstitial breast HDR 
implants. In their study, the lowest value of DNR is 
reported for 10 mm source step size. The effect of 
catheter separation is studied at 5 mm source step 
size. The catheter separation was increased from 10 to 
20 mm, for which the value of DNR reported to be 
increased from 0.15 to 0.22. While in the present study, 
QIs were evaluated for the above mentioned values of 
ISS and ICS and lowest DNR is found at ISS = 1.0 cm 
and ICS = 1.0 cm, where ISS =1.0 cm is same as 10 mm 
source step size. 
From the results of the present study, it can be 
concluded that in HDR ISBT implants the GOV 
provides an optimum outcome with regard to afore 
mentioned QIs, TCP, and NTCP, and is best achieved 
nearly uniform dose distribution within the implanted 
volume. While HDR ISBT implants done using 
classical dosimetry systems or non- optimization 
process lead to unsatisfactory results. It is also seen 
that on the basis of CI, EI and NTCP plots, no 
conclusion can be drawn as to what values of ICS and 
I S S  ( a n d  I P S )  w o u l d  b e  u s e d  t o  o p t i m i z e  t h e  s i n g l e  
and double plane HDR implants. While DHI, ODI, 
DNR and TCP clearly reveal that their optimal values 
are at ICS = 1.0 cm and ISS = 1.0 cm, for single plane 
implant and ICS = 1.0 cm, ISS = 1.0 cm, and IPS = 0.75 
to 1.25 cm, for double plane implants as shown in the 
study.  
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APPENDIX – A. Biologically Effective 
Equivalent Uniform Dose (BEEUD) for 
Tumors  
The tumor control probability (TCP) for uniform 
dose distribution within the target (tumor) volume is 
given by equation (7) in the text. To get maximum 
tumor cell killing in a tumor with uniform clonogenic 
cell density and avoid necrosis of the normal tissue 
present within the target volume, the dose distribution 
within the target volume should be uniform [18, 27, 
28]. However in HDR interstitial implants uniform 
dose distribution is rarely achieved. Hence the 
biologically effective dose (BED) or TCP calculated on 
the basis of the dose that corresponds to the isodose 
surface which encompasses the target volume or mean 
or median target dose would not be an appropriate 
representative to predict an accurate treatment 
outcome. Therefore, to account for non – uniform dose 
distribution, the target volume is divided into n 
number of sub-volumes (voxels). The number of 
sub-volumes depends on the volume of the target and 
user choice. The larger the number of the sub-volumes 
the more accurate the calculations. If the volume of 
each voxel is small enough, the dose distribution 
within the voxel may be considered uniform. Now the 
TCP is calculated voxel by voxel, and net TCP for 
entire target volume is given by product of all voxel 
based TCPs, which can be written as 
TCP =    Πi exp[ - ρ vi exp( - αBEDti)]        ….  (a) 
Where BEDti is the BED of ith voxel of volume vi 
of the target. Here i = 1, 2, 3, ………n. Equation (a) 
may be written as   
TCP =    exp[ - ρ Σi vi exp( - αBEDti)]        ….  (b) 
Let us assume that Biologically Effective 
Equivalent Uniform Dose (BEEUD) is the biological 
dose that produces equivalent biological effect to that 
of an absolutely uniform dose delivered to the entire 
target volume V. For such type of dose TCP is given 
by 
 TCP  =  exp[  -  ρ V exp( - αBEEUDt) ]       … .   ( c )  
By equating and rearranging the equations (b) 
and (c), we get an expression of BEEUD for tumor and 
may be written by 
 BEEUDt = (1/α) ln[(1/V)Σivi exp( - α BEDti) ]        
…. (d) 
Where i = 1, 2, 3, ………n.      In the calculation of 
TCP, for non-uniform dose distribution within the 
tumor, the use of BEEUD is an appropriate term 
instead of BED.     
APPENDIX – B. Biologically Effective 
Equivalent Uniform Dose (BEEUD) for Normal 
Tissues 
The Biologically Effective Equivalent Uniform 
Dose (BEEUD) derived in Appendix – A can not be 
applied to predict NTCP because dose distribution in 
normal tissue / organ and the NTCP formulae are not 
similar to that of the tumor. The BEEUD for normal 
tissue / organ is derived using NTCP model, and is 
given in equation (11). The dose distribution within 
normal tissue / organ is highly heterogeneous. Hence 
to derive BEEUD for such a dose distribution, entire 
volume of the normal tissue / organ is divided into n 
number of sub-volumes (voxels), similar to that of 
target volume. Accuracy of the NTCP depends on the 
number of sub-volumes. If the volume of each voxel is 
small enough, the dose distribution within the voxel 
may be considered uniform. In reality, the dose 
gradient within adjacent normal tissues / organs to 
the target volume is too high, so it is not possible to 
h a v e  u n i f o r m  d o s e  d i s t r i b u t i o n  i n  a n y  v o x e l .   T h e  
NTCP equation for ith voxel is written as 
NTCPi = exp[ - N0 (Vi/V0)-k exp( - α BEDni)]   ….  (e) 
The NTCP is not an additive term of the volume, 
so the NTCPs of the voxels can not provide net NTCP 
of entire normal tissue / organ volume. For the 
purpose, equation (e) may be written in the additive 
form of the volume and new term is known as the 
NTCP factor (NTCPF). By taking logarithm of both 
sides of equation (e), we have 
ln(NTCPi) =    - N0 (Vi/V0)-k exp( - α BEDni) Int. J. Med. Sci. 2008, 5 
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or  
[ - ln(NTCPi)] =    N0 (Vi/V0)-k exp( - α BEDni) 
or    
[ - ln(NTCPi)] -1/k = (N0)-1/k (Vi/V0) exp[(α/k) BEDni 
o r            
[(1/k) ln(NTCPi)]  =  (N0)-1/k (Vi/V0) exp[(α/k) BEDni 
Taking exponential to both sides we may write 
exp[(1/k) ln(NTCPi)] = exp[(N0)-1/k (Vi/V0) exp{(α/k) 
BEDni}] 
Write out L.H.S equals to NTCPF and may be 
written as 
NTCPFi = exp[(N0)-1/k (Vi/V0) exp{(α/k) BEDni}]     
…. (f) 
Where V0 is the reference volume of the normal 
tissue / organ and Vi is the volume of ith voxel of the 
normal tissue /organ. It may be assume that NTCPF 
for each voxel is mutually exclusive, hence, the 
NTCPF for entire volume of the normal tissue / organ 
can be written as 
NTCPF = exp[(N0)-1/k Σi{(Vi/V0) exp[(α/k) BEDni]}]   
…. (g) 
Let us assume that Biologically Effective 
Equivalent Uniform Dose (BEEUD) is the biological 
dose delivered uniformly to the entire organ volume 
V0 that produces equivalent NTCPF to that of 
equation (g), which may be given by 
NTCPF = exp[(N0)-1/k (V0/V0)exp{(α/k) BEEUDn}]  
or  
NTCPF = exp[(N0)-1/k exp{(α/k) BEEUDn}]    ….  (h) 
By equating and rearranging equations (g) & (h) 
we have an expression of BEEUD for normal tissue / 
organ, which may be given by 
BEEUDn = (k/α) ln[Σi{(Vi/V0) exp[(α/k) BEDi]}]      
…. (i)   
In the calculation of NTCP, the use of BEEUD, for 
normal tissue / organ with highly non-uniform dose 
distribution, would provide better radiobiological in 
sites.  